Keyphrases
Adverse Events
12%
Background Therapy
12%
Bleeding Episodes
12%
Bolus Dose
12%
Bypassing Therapy
12%
Concomitant Administration
12%
Factor VIII (FVIII)
100%
FEIBA
100%
Haemophilia with Inhibitors
100%
Hemarthrosis
12%
Hemophilia
100%
Hemostatic Therapy
100%
High-titer Inhibitor
12%
Immune Tolerance Induction
12%
Individual Response
12%
Minor Surgery
25%
Potential Treatments
12%
Recombinant Activated Factor VII (rFVIIa)
12%
Repeated Infusions
12%
Severe Haemophilia A
12%
Spiking Studies
12%
Successful Surgery
12%
Thrombin Generation
50%
Thrombosis
12%
Titer
12%
Treatment Options
12%
Medicine and Dentistry
Activated Prothrombin Complex
100%
Adverse Event
12%
Ex Vivo
12%
Haemophilia A
100%
Hemarthrosis
12%
Hemostat
100%
Immunological Tolerance
12%
Infusion
12%
Minor Surgery
25%
Patient Monitoring
12%
Patient with Hemophilia
100%
Thrombin
50%
Thrombosis
12%
Pharmacology, Toxicology and Pharmaceutical Science
Activated Prothrombin Complex
100%
Adverse Event
12%
Haemophilia A
100%
Hemarthrosis
12%
Hemostatic Agent
100%
Thrombin
50%
Thrombosis
12%